Product Name: CheerVitin Tablets
Indication: Specifically for the treatment and management of Feline Immunodeficiency Virus (FIV) infection.
Effectively inhibits viral replication, slows disease progression, improves clinical signs (such as chronic stomatitis, recurrent infections), and enhances the quality of life and life expectancy of infected cats.
Dosage: For oral use only.
The recommended dosage is 1 tablet per 4 kg of body weight, administered every 12 hours.
Duration of Treatment: The recommended treatment course is 5 to 7 days.
Administration should continue for at least 72 hours after the complete resolution of clinical symptoms and until two consecutive negative fecal antigen tests are obtained, as determined by the attending veterinarian.
| Body weight of cats (kg) | Dosage per Administration | Administration Interval |
| 1≤BW≤3 | 15 – 45 mg | Twice a day (every 8-12 hours) |
| 3<BW≤6 | 45 – 90 mg | |
| 6<BW≤10 | 90 – 150 mg | |
| 10≤BW | Calculate the dosage based on 15mg per kg of body weight. |
Withdrawal:
Not applicable
Package:
30 tablets per bottle
Storage:
Store tightly sealed below 25℃
Shelf life: 2 years
Warning：
This product contains a highconcentration, last-resort antibiotic.
Accidental ingestion by humans may cause serious health effects and contribute to antibiotic resistance. Seek medical advice immediately if ingested.
Important Notes
(1)Prescription-only: This is a prescription-only medicine. Administration MUST be under the direct supervision and guidance of a veterinarian.
(2)Complete the Course: Even if symptoms improve, administer the full course as prescribed to prevent relapse and resistance development.
(3)Monitoring: Regular monitoring of renal function and overall clinical response is essential during treatment.
(4)Adverse Reactions: Potential side effects may include vomiting, diarrhea, loss of appetite, or in rare cases neurological signs (e.g., tremors). Discontinue use and contact your veterinarian immediately if adverse reactions occur.
(5)THERAPEUTIC WARNING: While this product is a specific antiviral agent, the successful management of feline panleukopenia critically depends on timely and
aggressive supportive care to address dehydration, secondary infections, and nutritional support. This product does not replace essential fluid and electrolyte therapy.
For animal treatment only.
Product Name: Meropenem
Indication: For tthe treatment of severe systemic and/or localized infections caused by multi-drug resistant susceptible bacteria in dogs.
This veterinary medicinal product is a broad-spectrum carbapenem antibiotic. It is indicated where other antibiotics have
failed or are likely to be ineffective, based on culture and susceptibility testing.
Serious Respiratory Tract Infections (e.g., pneumonia)
Complicated Urinary Tract Infections (e.g., pyelonephritis)
Intra-abdominal Infections (e.g., peritonitis)
Skin and Soft Tissue Infections(e.g., deep pyoderma, wounds)
Bacterial Septicaemia.
NOTE: Its use should be reserved for cases confirmed or strongly suspected to involve multi-drug resistant organisms.
Dosage: For oral use only.
The recommended dose is 15 mg of meropenem per kg of body weight, administered every 8 to 12 hours.
The exact dosage, frequency, and duration of therapy MUST be determined by a veterinarian based on the type and severity of the infection, the causative organism’s susceptibility, and the patient’s renal function.
| Body weight of dogs (kg) | Dosage per Administration | Administration Interval |
| 1≤BW≤3 | 15 – 45 mg | Twice a day (every 8-12 hours) |
| 3<BW≤6 | 45 – 90 mg | |
| 6<BW≤10 | 90 – 150 mg | |
| 10≤BW | Calculate the dosage based on 15mg per kg of body weight. |
Withdrawal:
Not applicable
Package:
10 pieces/box
Storage:
Store tightly sealed below 25℃
Shelf life: 2 years
Warning：
This product contains a highconcentration, last-resort antibiotic.
Accidental ingestion by humans may cause serious health effects and contribute to antibiotic resistance. Seek medical advice immediately if ingested.
Important Notes
(1)Prescription-only: This is a prescription-only medicine. Administration MUST be under the direct supervision and guidance of a veterinarian.
(2)Complete the Course: Even if symptoms improve, administer the full course as prescribed to prevent relapse and resistance development.
(3)Monitoring: Regular monitoring of renal function and overall clinical response is essential during treatment.
(4)Adverse Reactions: Potential side effects may include vomiting, diarrhea, loss of appetite, or in rare cases neurological signs (e.g., tremors). Discontinue use and contact your veterinarian immediately if adverse reactions occur.
(5)Meropenem is a critically important antimicrobial. Inappropriate use will accelerate bacterial resistance, posing a threat to animal and public health.
Product Name: Fuzapladib Sodium for Injection
Strength: Fuzapladib Sodium 14 mg per vial
Vial 1: Sterile lyophilized powder containing 14 mg fuzapladib sodium, 52.5 mg D-mannitol, and 21 mg tromethamine
Vial 2: Sterile diluent (bacteriostatic water for injection) 3.9 mL, containing 1.8% w/v benzyl alcohol
For Use In: Dogs only
Actions & Indications:
Fuzapladib Sodium – A selective leukocyte function-associated antigen-1 (LFA-1) activation inhibitor
Indications:
Fuzapladib Sodium for Injection is indicated for the management of clinical signs associated with acute onset of pancreatitis in dogs.
Dosage:
0.4 mg (0.1 mL) per kg
Once daily for 3 consecutive days
| Body weight (kg) | Dose (mg) | Volume to Administer (mL) |
| 2.5 | 1.0 | 0.25 |
| 5.0 | 2.0 | 0.50 |
| 7.5 | 3.0 | 0.75 |
| 10.0 | 4.0 | 1.00 |
| 12.5 | 5.0 | 1.25 |
| 15.0 | 6.0 | 1.50 |
| 20.0 | 8.0 | 2.00 |
| 25.0 | 10.0 | 2.50 |
| 30.0 | 12.0 | 3.00 |
| 35.0 | 14.0 | 3.50 |
| 40.0 | 16.0 | 4.00 |
Reconstitution Procedures
Items needed:
Sterile lyophilized powder vial
Sterile diluent vial
Sterile 5 mL syringe for transfer of diluent
Sterile needle
Steps:
1.Using a sterile needle and syringe, withdraw 3.5 mL of the sterile diluent from the diluent vial
2.Slowly transfer the sterile diluent into the vial containing the sterile lyophilized powder through the stopper
3.Remove the needle and syringe from the vial. Discard unused diluent, syringe, and needle
4.Gently swirl the vial until the powder is fully reconstituted into solution, leaving no visible residue or undissolved material
5.Before each use, gently swirl to ensure a uniform solution
6.Draw up the appropriate dose using a new sterile needle and syringe
7.Administer the dose promptly after drawing into the dosing syringe
Note:
More sterile diluent is supplied than the 3.5 mL needed for reconstitution
No other diluent should be used
Storage After Reconstitution
| Condition | Temperature | Stability |
| Refrigerated | 36°F to 46°F (2°C to 8°C) | 28 days |
Mechanism of Action:
Fuzapladib sodium is a selective inhibitor of leukocyte function-associated antigen-1 (LFA-1) activation. LFA-1 is an integrin expressed on the surface of leukocytes that plays a critical role in the inflammatory response. By inhibiting LFA-1 activation, fuzapladib reduces the recruitment and activation of neutrophils and other inflammatory cells to the pancreas, thereby mitigating the systemic inflammatory response associated with acute pancreatitis
Clinical Context:
Acute pancreatitis is a common inflammatory condition in dogs characterized by premature activation of digestive enzymes within the pancreas, leading to autodigestion, inflammation, and potential systemic complications. The inflammatory process recruits neutrophils and other leukocytes, releasing cytokines that exacerbate tissue damage. Fuzapladib targets the LFA-1-mediated leukocyte migration to interrupt this inflammatory cascade.
Contraindications:
Do not use in dogs with a known hypersensitivity to fuzapladib sodium
Warnings:
Fuzapladib sodium is a selective inhibitor of leukocyte function-associated antigen-1 (LFA-1) activation. LFA-1 is an integrin expressed on the surface of leukocytes that plays a critical role in the inflammatory response. By inhibiting LFA-1 activation, fuzapladib reduces the recruitment and activation of neutrophils and other inflammatory cells to the pancreas, thereby mitigating the systemic inflammatory response associated with acute pancreatitis
Clinical Context:
User Safety Warnings
Not for use in humans. Keep out of reach of children
Accidental self-injection: Seek medical advice immediately and show the package insert or label to the physician
Accidental skin contact: Wash the exposed skin with water for at least 15 minutes. If redness and swelling occur, seek medical advice immediately
Accidental eye exposure: Wash eyes with water for at least 15 minutes. If wearing contact lenses, rinse first, then remove and continue rinsing
Accidental ingestion: Rinse mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical advice immediately
Pregnancy/Breastfeeding: Limited data on teratogenic effects. Pregnant, breastfeeding, or women planning to become pregnant should avoid direct contact
Hypersensitivity: Anyone with known hypersensitivity to fuzapladib sodium or any excipients should avoid contact
Adverse Reactions
Adverse events reported in clinical study (n=31 fuzapladib-treated dogs)
| Adverse Event | Fuzapladib (n=31) | Placebo (n=30) |
| Anorexia | 5 (16.1%) | 2 (6.7%) |
| Digestive tract disorders | 5 (16.1%) | 3 (10.0%) |
| Respiratory tract disorders | 4 (12.9%) | 3 (10.0%) |
| Hepatopathy, jaundice | 4 (12.9%) | 2 (6.7%) |
| Abnormal urine | 3 (9.7%) | 2 (6.7%) |
| Diarrhea | 3 (9.7%) | 1 (3.3%) |
| Arrhythmia | 2 (6.5%) | 1 (3.3%) |
| Cardiac arrest | 2 (6.5%) | 0 |
| Hyperthermia | 2 (6.5%) | 0 |
| Pruritus, urticaria | 2 (6.5%) | 0 |
| Hypersalivation | 2 (6.5%) | 0 |
| Anaphylaxis | 1 (3.2%) | 0 |
| Cerebral edema | 1 (3.2%) | 0 |
Digestive tract disorders included regurgitation, vomiting, flatulence, nausea
Respiratory tract disorders included pneumonia, inspiratory crackles, tachypnea, dyspnea
Abnormal urine included proteinuria, hematuria, malodorous urine
Other observed events:
Heart murmur (1 fuzapladib, 2 placebo)
Limb edema (1 fuzapladib, 2 placebo)
SC swelling, bruising at injection site (1 fuzapladib, 1 placebo)
Tremor/shivering/shaking (1 fuzapladib, 1 placebo)
Hypertension (1 fuzapladib
Precautions:
Fuzapladib sodium is a selective inhibitor of leukocyte function-associated antigen-1 (LFA-1) activation. LFA-1 is an integrin expressed on the surface of leukocytes that plays a critical role in the inflammatory response. By inhibiting LFA-1 activation, fuzapladib reduces the recruitment and activation of neutrophils and other inflammatory cells to the pancreas, thereby mitigating the systemic inflammatory response associated with acute pancreatitis
Clinical Context:
Protein Binding:
It is highly protein bound
Use with caution with other medications that are highly protein bound (e.g., NSAIDs, anti-emetics, antibiotics, diuretics, behavioral medications)
Concomitant use with other protein-bound drugs has not been studied in dogs
Populations Not Evaluated
| Population | Safety Status |
| Dogs with cardiac disease | Not evaluated |
| Dogs with hepatic failure | Not evaluated |
| Dogs with renal impairment | Not evaluated |
| Pregnant dogs | Not evaluated |
| Lactating dogs | Not evaluated |
| Dogs intended for breeding | Not evaluated |
| Dogs less than 6 months of age | Not evaluated |
Concurrent Medications:
Concurrent medications used during the pilot effectiveness study included, but were not limited to, pain medications (excluding NSAIDs), antiemetics, parasiticides, vaccinations, and medications used to treat well-controlled pre-existing conditions.
Drug Interactions:
Due to high protein binding, potential for displacement interactions with other highly protein-bound drugs
Drug compatibility should be monitored in patients requiring adjunctive therapy
Concomitant use with NSAIDs has not been studied
Withdrawal Period:
Not applicable (for companion animals)
Package:
Each carton contains：
One vial of sterile lyophilized powder (14 mg fuzapladib sodium)
One vial of sterile diluent (3.9 mL bacteriostatic water for injection)
Storage:
Unopened kits (dry powder)：
Store at controlled room temperature
Reconstituted product：
Refrigerated at 36°F to 46°F (2°C to 8°C)
Stable for 28 days
Shelf Life:
Refer to packaging expiry date
For animal use only.
Product Name: Fludrocortisone Tablet
Strength: Fludrocortisone Acetate 0.1 mg
Actions & Indications:
For the treatment of hypoadrenocorticism (Addison‘s disease) in dogs and cats as mineralocorticoid replacement therapy
Indications:
Fuzapladib Sodium for Injection is indicated for the management of clinical signs associated with acute onset of pancreatitis in dogs.
Dosage and Administration:
For Dogs :
Maintenance Dose Range:
0.01 – 0.08 mg/kg/day
Required dose typically increases over time
| Parameter | Value |
| Starting dose | 0.01 – 0.02 mg/kg/day |
| Frequency | Once daily or divided twice daily (every 12 hours) |
For Cats :
Maintenance Dose Range:
0.05 – 0.10 mg/kg/day
Required dose typically increases over time
| Parameter | Value |
| Dose | 0.05 – 0.10 mg per cat |
| Frequency | Twice daily (every 12 hours) |
| Alternative | 0.1 mg/cat once daily |
Administration Instructions:
Administer orally with or without food; if vomiting occurs on an empty stomach, give with food
Do not stop this medication abruptly, as serious side effects may occur
If a dose is missed, give it as soon as remembered; if close to next dose, skip the missed dose — do not double dose
Most pets will need additional glucocorticoid supplementation, especially during times of stress
Wash hands after administering this medication
Mechanism of Action:
Fludrocortisone acetate is a synthetic mineralocorticoid that acts on the kidney to promote sodium retention and potassium excretion, thereby regulating electrolyte and water balance in the body . It also possesses some intrinsic glucocorticoid activity, which may reduce the need for additional glucocorticoid supplementation in some patients .
Pharmacokinetics:
Absorption: Rapidly and completely absorbed after oral administration
Onset of action: 1-2 hours
Peak blood level: 4-8 hours
Protein binding: 70-80% bound to serum proteins
Half-life in dogs: 30 minutes (IV administration)
Precautions:
1.his is a prescription drug and must be used under veterinary supervision
2.Off-label use: This medication is not FDA-approved for use in animals; it is used according to veterinary directions
3.Do not stop abruptly — gradual withdrawal may be necessary to avoid adrenal insufficiency
4.Electrolytes (sodium and potassium) and kidney values should be monitored regularly:
Initially: every 1-2 weeks
Once stabilized: every 3-6 months
5.Dogs may require increasing doses over time to maintain normal electrolyte levels
6.Salt supplementation is no longer routinely recommended as it is not very effective
7.If a dog develops signs of hyperadrenocorticism at usual doses, first withdraw any additional glucocorticoid supplementation before considering dose reduction
8.Keep out of reach of children
Withdrawal Period:
Not applicable (for companion animals)
Package:
Bottles or blister packs containing 0.1 mg tablets
Storage:
Store at room temperature between 59°F and 86°F (15°C to 30°C). Protect from moisture and excessive heat .
Shelf Life:
Refer to packaging expiry date
Product Name: Toceranib Phosphate Tablets
Strength: 10mg/tablet , 15mg/tablet , 50mg/tablet
Package: 10 tablets per blister strip.
For Use In: Dogs.
Main component: Each tablet contains 10 mg, 15 mg, or 50 mg of Toceranib (as Toceranib Phosphate).
Actions & Indications:
Toceranib is a selective receptor tyrosine kinase inhibitor primarily targeting KIT, PDGFR, and VEGFR. By inhibiting these signaling pathways crucial for tumor cell proliferation, survival, and angiogenesis, it exerts an antitumor effect.
Indicated for the treatment of recurrent or metastatic canine mast cell tumors (MCT), particularly in cases where complete surgical excision is not possible or metastasis has occurred.
Dosage: For oral use only.
Administration with food is recommended to reduce gastrointestinal irritation.
Recommended Dosage: 3.25 mg/kg body weight, administered every other day (e.g., Monday, Wednesday, Friday).
| Dog Body Weight | Number of Tablets | ||||
| Pounds | kg | Dose | 10mg | 15mg | 50mg |
| 11.0-11.8 | 5.0-5.3 | 15mg | 1 | ||
| 11.9-15.2 | 5.4-6.9 | 20mg | 2 | ||
| 15.3-18.5 | 7.0-8.4 | 25mg | 1 | 1 | |
| 18.6-22.0 | 8.5-10.0 | 30mg | 2 | ||
| 22.1-25.4 | 10.1-11.5 | 35mg | 2 | 1 | |
| 25.5-28.7 | 11.6-13.0 | 40mg | 1 | 2 | |
| 28.8-32.2 | 13.1-14.6 | 45mg | 3 | ||
| 32.3-35.5 | 14.7-16.1 | 50mg | 1 | ||
| 35.6-38.8 | 16.2-17.6 | 55mg | 1 | 3 | |
| 38.9-42.3 | 17.7-19.2 | 60mg | 1 | 1 | |
| 42.4-45.6 | 19.3-20.7 | 65mg | 1 | 1 | |
| 45.7-50.7 | 20.8-23.0 | 70mg | 2 | 1 | |
| 50.8-59.3 | 23.1-26.9 | 80mg | 2 | 1 | |
| 59.4-65.9 | 27.0-29.9 | 95mg | 3 | 1 | |
| 66.0-71.2 | 30.0-32.3 | 100mg | 2 | ||
| 71.3-76.3 | 32.4-34.6 | 110mg | 1 | 2 | |
| 76.4-79.6 | 34.7-36.1 | 115mg | 1 | 2 | |
| 79.7-84.7 | 36.2-38.4 | 120mg | 2 | 2 | |
| 84.8-94.8 | 38.5-43.0 | 130mg | 2 | 2 | |
| 94.9-105.0 | 43.1-47.6 | 150mg | 3 | ||
| 105.1-110.0 | 47.7-49.9 | 160mg | 1 | 3 | |
| 110.1-113.5 | 50.0-51.5 | 165mg | 1 | 3 | |
| 113.6-118.6 | 51.6-53.8 | 170mg | 2 | 3 | |
| 118.7-128.8 | 53.9-58.4 | 180mg | 2 | 3 | |
| 128.9-138.9 | 58.5-63.0 | 200mg | 4 | ||
| 139.0-144.0 | 63.1-65.3 | 210mg | 1 | 4 | |
Dosage Adjustment:
The starting dose is typically 3.25 mg/kg every other day. Your veterinarian will fine-tune the dose within the recommended range based on the individual dog’s tolerance (particularly to adverse effects) and therapeutic response.
Treatment Course:
Treatment should continue until disease progression or intolerable toxicity occurs. Do not discontinue or alter the dosing schedule without veterinary instruction.
Contraindications & Warnings:
Absolute Contraindications:
Hypersensitivity to toceranib or any excipient.
Dogs with severe hepatic impairment.
Dogs with active, severe gastrointestinal bleeding or ulceration.
STRICTLY PROHIBITED for use in humans, cats, or other animals.
Relative Contraindications / Use with Caution:
Mild to moderate hepatic impairment.
Renal insufficiency.
History of cardiac disease.
Concurrent use with NSAIDs or corticosteroids may increase the risk of gastrointestinal toxicity and renal injury.
Reproductive Safety:Safety in pregnant, lactating bitches or breeding stud dogs has not been established.
Contraindicated.
Adverse Reactions
Common adverse reactions are related to its mechanism of action and are often manageable with dose adjustments or supportive care.
Very Common (>10%):Diarrhea, vomiting, decreased appetite, lethargy, weight loss, hypoproteinemia
(hypoalbuminemia).
Common (1-10%):Gastrointestinal hemorrhage (melena, hematochezia), pancreatitis, elevated liver enzymes, neutropenia, thrombocytopenia, proteinuria, hypertension, footpad fissures/pain.
Uncommon but Serious:Gastrointestinal perforation, severe hemorrhage, nephrotic syndrome, heart failure, arterial thromboembolism.
Monitoring Requirements:Regular monitoring (e.g., every 2-4 weeks) with complete blood count (CBC), serum biochemistry (focus on liver and kidney function, electrolytes, albumin), and urinalysis is required during treatment.
Drug Interactions
CYP450 Enzyme Substrate Drugs:Toceranib may affect the plasma concentrations of drugs metabolized by
CYP3A4, 2B11, and 2D15.
Highly Protein-Bound Drugs:Displacement interactions may occur, affecting the plasma concentrations of each drug.
Anticoagulants (e.g., Warfarin):Increases the risk of bleeding.
QT-Prolonging Drugs:Concurrent use may increase the risk of arrhythmia.
Inform your veterinarian of all medications (including prescription, over-the-counter, and supplements) the dog is
receiving.
Product Name: Pimobendan Tablets
Strength: 1.25mg 2.50mg 5.00mg
Package: 10 PCS/box
For Use In: Dogs
Actions & Indications:
For the treatment of canine congestive heart failure (CHF) caused by:
Dilated cardiomyopathy (DCM)
Chronic valvular disease (CVD / mitral valve insufficiency)
Dosage:
For Dogs
Recommended dosage: 0.25 – 0.5 mg pimobendan per kg body weight, divided into two daily doses
(every 12 hours)
| Body weight (kg) | Daily Dose (mg) | 1.25mg Tablet Count (per dose) | 2.50mg Tablet Count (per dose) | 5.00mg Tablet Count (per dose) |
| 2.5-5.0 | 0.625-1.25 | 1/2-1 | / | / |
| 5.1-10.0 | 1.25-2.5 | 1-2 | 1/2-1 | / |
| 10.1-15.0 | 2.5-3.75 | 2-3 | 1-1.5 | / |
| 15.1-20.0 | 3.75-5.0 | 3-4 | 1.5-2 | 1 |
| 20.1-30.0 | 5.0-7.5 | / | 2-3 | 1-1.5 |
| 30.1-40.0 | 7.5-10.0 | / | 3-4 | 1.5-2 |
| >40.0 | Calculate by weight | / | / | Use combination of strengths |
Note: The daily dose should be divided into two equal doses administered approximately 12 hours apart (e.g.,morning and evening).
Administration Instructions:
1.TAdminister orally, preferably one hour before feeding (on an empty stomach)
2.Tablets may be given whole or crushed and mixed with a small amount of food
3.Do not split tablets unless using a proper tablet splitter to ensure dose accuracy
4.Treatment is typically long-term and should not be discontinued abruptly
Mechanism of Action:
Pimobendan is a dual-action inodilator:
Positive inotropic effect: Increases myocardial contractility by sensitizing cardiac troponin C to calcium ions
Vasodilatory effect: Inhibits phosphodiesterase III, leading to vasodilation and reduced cardiac afterload
Administration Instructions:
1.TAdminister orally, preferably one hour before feeding (on an empty stomach)
2.Tablets may be given whole or crushed and mixed with a small amount of food
3.Do not split tablets unless using a proper tablet splitter to ensure dose accuracy
4.Treatment is typically long-term and should not be discontinued abruptly
Adverse Reactions:
In rare cases:
Gastrointestinal upset (vomiting, diarrhea, anorexia)
Increased heart rate or arrhythmias
Lethargy
Very rare:
Hypersensitivity reactions (rash, facial swelling)
Most reactions are mild and reversible upon dose adjustment or discontinuation
Precautions:
1.This is a prescription drug and must be used under veterinary supervision
2.Not recommended for use in dogs with hypertrophic cardiomyopathy (HCM) or aortic stenosis
3.Use with caution in dogs with diabetes mellitus
4.Do not exceed the recommended dosage
5.Keep out of reach of children
6.Not for use in humans
Discontinuation:
Caution should be exercised when used concomitantly with:
Calcium channel blockers (e.g., diltiazem, verapamil)
Beta-blockers (e.g., propranolol, atenolol)
Diuretics (e.g., furosemide) – monitor for electrolyte imbalance
Package:
10 tablets per blister, 1 blisters per box (10 tablets per box)
Aluminum-plastic blister pack
Storage:
Store tightly sealed below 25°C, protected from light and moisture
Shelf life: 2 years
For animal use only.
Product Name：Sirolimus Delayed-Release Tablets
Active Ingredient: Sirolimus – A macrocyclic lactone compound with antiproliferative properties
Indications： (sirolimus delayed-release tablets) is indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM) .
Subclinical HCM refers to cats with left ventricular (LV) hypertrophy (LV wall thickness of ≥6 mm at end diastole by 2D or M-mode assessment) in the absence of :
Systemic hypertension
Other causes of compensatory myocardial hypertrophy
Current or historic symptoms of congestive heart failure
Arterial thromboembolism
Severe LV outflow tract obstruction
Usage and Dosage：
For Cats
| Number of Tablets | |||
| Body Weight (kg) | 0.4 mg | 1.2 mg | 2.4 mg |
| 2.5-3.2 | 2 | 0 | 0 |
| 3.3-4.8 | 0 | 1 | 0 |
| 4.9-6.4 | 1 | 1 | 0 |
| 6.5-9.6 | 0 | 0 | 1 |
| >9.6 | 0 | 1 | 1 |
Administration Instructions:
1.Administer once weekly on the same day each week
2.Tablets should be swallowed whole and not chewed
3.Do not split or crush tablets
4.Administer in conjunction with a meal
5.Always store tablets in the original packaging and only remove required tablets at the time of dosing
Contraindications:
Do not use in cats with :
Diabetes mellitus – Discontinue immediately if a cat receiving treatment is diagnosed with diabetes mellitus. Administration to a cat that
developed diabetes mellitus was associated with the development of diabetic ketoacidosis and death.
Pre-existing liver disease
Notes:
Before Treatment ：
A diagnosis of subclinical HCM should be made by comprehensive physical examination including blood pressure measurement and echocardiography
Conduct screening bloodwork including a serum biochemical profile to rule out pre-existing liver dysfunction
During Treatment ：
Bloodwork should be repeated 1 to 2 months following initiation of treatment, and every 6 to 12 months thereafter
Treatment with FELYCIN®-CA1 has been associated with elevation of ALT and AST
Adverse reactions:
| Adverse Event | Notes |
| Transaminase elevation (ALT/AST) | Most common; up to 2X ULN |
| Diabetic ketoacidosis and death | In cats that developed diabetes mellitus |
| Gastrointestinal effects | Possible |
| Immunosuppression | Available information does not indicate immunosuppression at the doses administered |
Storage conditions:
Store at controlled room temperature; protect from light and moisture. Keep in original packaging.
Package:
Blister packaging – store tablets in original packaging until use
For animal use only.
Product Name: Dexmedetomidine Hydrochloride Injection
Strength: 0.5 mg/mL(Dexmedetomidine Hydrochloride 0.5 mg per mL)
Indications:
For use as a sedative and analgesic in dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures. Also indicated for use as a preanesthetic to general anesthesia in dogs and cats.
Active Ingredient
Dexmedetomidine Hydrochloride – A synthetic alpha₂-adrenoceptor agonist with sedative and analgesic properties.
Each mL contains: Methylparaben 1.6 mg, Propylparaben 0.2 mg, Sodium Chloride 9.0 mg, Water for Injection q.s.
pH adjusted with Hydrochloric Acid or Sodium Hydroxide as needed.
Dosage and Administration
For Dogs
| Indication | Route | Dosage |
| Sedation & Analgesia | IM | 500 mcg/m² |
| Sedation & Analgesia | IV | 375 mcg/m² |
| Preanesthesia | IM | 125 or 375 mcg/m² |
Note: The mcg/kg dosage decreases as body weight increases. Accurate dosing is not possible in dogs
weighing less than 2 kg (4.4 lb) due to small volume of administration
For Cats
| Indication | Route | Dosage |
| Sedation, Analgesia & Preanesthesia | IM | 40 mcg/kg |
Administration Instructions
1.It is recommended that animals be fasted for 12 hours before treatment
2.An eye lubricant should be applied to cats to prevent corneal desiccation due to reduced blink reflex
3.Following injection, allow the animal to rest quietly for 15 minutes
4.Sedation and analgesia occur within 5 to 15 minutes, with peak effects at 30 minutes after administration
Contraindications
Do not use in animals with:
Cardiovascular disease
Respiratory disorders
Liver or kidney diseases
Shock, severe debilitation, or stress due to extreme heat, cold or fatigue
Precautions
1.This is a prescription drug and must be used under veterinary supervision
2.Apnea may occur; additional oxygen should be supplied if needed
3.Atipamezole may be used to reverse the effects of dexmedetomidine in dogs (reverses both sedative and analgesic effects)
4.In cats, atipamezole has not been evaluated as a routine reversal agent
5.Nervous or excited animals may exhibit reduced pharmacological response
6.Anticholinergic agents (e.g., atropine) given simultaneously with or after dexmedetomidine is not
recommended (may cause adverse cardiovascular effects)
7.Do not use in animals with preexisting hypotension, hypoxia, or bradycardia
8.Keep out of reach of children
For animal use only.